Abstract:Objectives To detect the early subclinical myocardial injury during and shortly after epirubicin exposure in asymptomatic patients with large B-cell non-Hodgkin lymphoma by two-dimensional speckle tracking imaging and high sensitive cardiac troponin T (hs-cTnT) and to investigate whether alterations of myocardial strains and high sensitive cardiac troponin T could predict future cardiac dysfunction in patients after epirubicin exposure. Methods Seventy-five patients aged 53.9 ± 13.8 years with newly-diagnosed large B-cell non-Hodgkin lymphoma treated with anthracycline were studied. Blood collection and echocardiography were performed at baseline, 1 day after the third cycle, and 1 day after chemotherapy completion. After 4–6 months of chemotherapy, echocardiography was followed up. Levels of cTnT were detected with a highly sensitive assay. Longitudinal (LS), circumferential (CS) and radial strain (RS) were calculated using two-dimensional speckle tracking echocardiography. Left ventricular ejection fraction (LVEF) was analysed by real-time 3D echocardiography. Cardiotoxicity was defined according to the guidelines (Cardiac Review and Evaluation Committee of Trastuzumab-associated cardiotoxicity, CREC) as a reduction of the left ventricular ejection fraction (LVEF) of ≥5% to <55% with symptoms of heart failure or an asymptomatic reduction of the LVEF of ≥10% to <55%. Results LVEF remained stable and within normal limits in the whole course of chemotherapy. However it was decreased from 65.0 ± 3.8% at baseline to 60.8 ± 4.9% during follow-up (p = 0.000). Fourteen patients (18.67%) developed cardiotoxicity 4–6 months after treatment. Global LS (-18.5 ± 1.7% vs -16.5 ± 1.9%), CS (-20.9 ± 2.9% vs -19.3 ± 3.5%), RS (39.2 ± 6.4% vs 35.3 ± 5.2%) were markedly reduced and cTnT was elevated from 0.0010 ± 0.0020 ng/ml to 0.0063 ± 0.0089 ng/ml (p all<0.01) at the completion of the third cycle of chemotherapy compared with baseline values. The correlation between the increment of cTnT levels and percentage of global LS deduction was good (rho = 0.60, p < 0.01), and percentage of CS and RS decrease was modest (rho = 0.31, -0.29, respectively, p all <0.01). A >15.9% decrease in longitudinal strain ( sensitivity: 86%, specificity: 75%, AUC = 0.815, P = 0.001) and a >0.004ng/ml elevation in cTnT levels (sensitivity: 79%, specificity: 64%, AUC = 0.757, P = 0.005) from baseline to the third cycle of chemotherapy predicted later cardiotoxicity. The decrease of longitudinal strain between baseline and the third cycle of chemotherapy remained the only independent predictor of cardiotoxicity (p = 0.000). Conclusions Two-dimensional speckle tracking imaging combined with high sensitive cTnT may provide a reliable and accurate non-invasive method to detect subtle myocardial injury and to predict cardiac dysfunction in patients receiving anthracycline-based chemotherapy. The decrease of longitudinal strain is the only independent predictor of cardiotoxicity.

Subclinical Anthracycline-Induced Cardiotoxicity in the Long - Term Follow-Up of Lymphoma Survivors: A Multi-Layer Speckle Tracking Analysis.

Anthracycline Induced Inconsistent Left Ventricular Segmental Systolic Function Variation in Patients with Lymphoma Detected by Three-Dimensional Speckle Tracking Imaging

Evaluation of Left Ventricular Function with Left Atrio-Ventricular Longitudinal Strain in Patients with Lymphoma Underwent Anthracycline Therapy

Use of echocardiography to monitor myocardial damage during anthracycline chemotherapy

GW24-e1764 Speckle Tracking Imaging Combined with High Sensitive Cardiac Troponin T in Early Detection and Prediction of Cardiotoxicity During Anthracycline-based Chemotherapy

Three-Dimensional Speckle Tracking Echocardiography for Assessment of Right Ventricular Morphological Changes and Dysfunction on Long-term Lymphoma Survivors Received Anthracycline Therapy

Early detection of anthracycline-induced cardiotoxicity in long-term survivors of acute lymphoblastic leukemia treated with low cumulative dose

Early Detection of Anthracycline-Induced Cardiotoxicity Using Two-Dimensional Speckle Tracking Echocardiography.

Evaluation of Subclinical Dysfunction of Left Ventricle Induced by Anthracycline in Patients with Lymphoma by ;Two-Dimensional Speckle Tracking Echocardiography and Real-Time Three-Dimensional Echocardiography

Early Subclinical Dysfunction of Right Cardiac System Induced by Anthracycline Manifested As Morphological Changes

Measurements of longitudinal strain of left ventricle using speckle tracking imaging in breast cancer patients treated by anthracyclines and trastuzumab

Difference of left ventricular segmental longitudinal strain in patients with lymphoma receiving anthracycline detected by three dimensional speckle tracking imaging

Assessment of left heart dysfunction to predict doxorubicin cardiotoxicity in children with lymphoma

Right Ventricular Ejection Fraction Assessed by Three-Dimensional Echocardiography Is Associated with Long-Term Adverse Clinical Cardiac Events in Patients with Anthracycline-Induced Cardiotoxicity

Anthracycline‐induced cardiotoxicity on regional myocardial work and left ventricular mechanical dispersion in adolescents and young adults in post‐lymphoma remission

Assessment of Biventricular Systolic Strain Derived from the Two-Dimensional and Three-Dimensional Speckle Tracking Echocardiography in Lymphoma Patients after Anthracycline Therapy

Permanent longitudinal strain damage of cardiotoxic drugs in childhood cancer: What is the safe level?

Early Anthracycline-Induced Cardiotoxicity Monitored by Echocardiographic Doppler Parameters Combined with Serum Hs-Ctnt.

Evaluation of left ventricular myocardial dysfunction induced by anthracyclines in patients with diffuse large B-cell lymphoma by three-dimensional speckle tracking imaging

The Early Variation of Left Ventricular Twisting Function in Patients with Lymphoma Received Anthracycline Therapy Assessed by Three-Dimensional Speckle Tracking Echocardiography.

Subclinical Cardiac Dysfunction in Childhood Cancer Survivors on 10-Years Follow-Up Correlates With Cumulative Anthracycline Dose and Is Best Detected by Cardiopulmonary Exercise Testing, Circulating Serum Biomarker, Speckle Tracking Echocardiography, and Tissue Doppler Imaging